Summary
Biogen Idec Inc. reported its financial results for the quarterly period ended March 31, 2005. The company, a significant player in the biotechnology sector, presented unaudited financial statements for the three months ended March 31, 2005, and March 31, 2004. Investors should pay close attention to the changes in revenue, profitability, and the overall financial health as indicated by the balance sheet and cash flow statements. This filing provides a snapshot of Biogen Idec's performance in early 2005, following its merger. Key areas to monitor include product sales, research and development expenses, and any significant legal or operational developments. The Management's Discussion and Analysis (MD&A) section is crucial for understanding the underlying drivers of the reported financial figures and the company's outlook.
Key Highlights
- 1Biogen Idec Inc. filed its quarterly report (10-Q) for the period ended March 31, 2005.
- 2The report contains unaudited condensed consolidated financial statements for the three months ended March 31, 2005 and 2004.
- 3Key financial statements include Statements of Income, Balance Sheets, and Statements of Cash Flows.
- 4The filing indicates that the company has met its reporting requirements for the preceding 12 months and the past 90 days.
- 5Biogen Idec is classified as an accelerated filer.
- 6As of April 19, 2005, 344,627,764 shares of common stock were outstanding.
- 7The report includes sections on Legal Proceedings and Unregistered Sales of Equity Securities.